B-intervention	0	3	Tai
I-intervention	4	7	chi
O	7	8	,
O	9	17	cellular
O	18	30	inflammation
O	30	31	,
O	32	35	and
O	36	49	transcriptome
O	50	58	dynamics
O	59	61	in
O	62	68	breast
O	69	75	cancer
O	76	85	survivors
O	86	90	with
B-condition	91	99	insomnia
O	99	100	:
O	101	102	a
O	103	113	randomized
O	114	124	controlled
O	125	130	trial
O	130	131	.

O	132	136	Mind
O	136	137	-
O	137	141	body
O	142	151	therapies
O	152	156	such
O	157	159	as
O	160	163	Tai
O	164	167	Chi
O	168	171	are
O	172	178	widely
O	179	183	used
O	184	186	by
O	187	193	breast
O	194	200	cancer
O	201	210	survivors
O	210	211	,
O	212	215	yet
O	216	223	effects
O	224	226	on
O	227	239	inflammation
O	240	243	are
O	244	247	not
O	248	253	known
O	253	254	.

O	255	259	This
O	260	265	study
O	266	278	hypothesized
O	279	283	that
O	284	287	Tai
O	288	291	Chi
O	292	296	Chih
O	297	298	(
O	298	301	TCC
O	301	302	)
O	303	308	would
O	309	315	reduce
O	316	324	systemic
O	324	325	,
O	326	334	cellular
O	334	335	,
O	336	339	and
O	340	347	genomic
O	348	355	markers
O	356	358	of
O	359	371	inflammation
O	372	374	as
O	375	383	compared
O	384	388	with
O	389	398	cognitive
O	399	409	behavioral
O	410	417	therapy
O	418	421	for
O	422	430	insomnia
O	431	432	(
O	432	435	CBT
O	435	436	-
O	436	437	I
O	437	438	)
O	438	439	.

O	440	442	In
O	443	447	this
O	448	458	randomized
O	459	464	trial
O	465	468	for
O	469	472	the
O	473	482	treatment
O	483	485	of
O	486	494	insomnia
O	494	495	,
B-total-participants	496	498	90
B-eligibility	499	505	breast
I-eligibility	506	512	cancer
I-eligibility	513	522	survivors
I-eligibility	523	527	with
I-eligibility	528	536	insomnia
O	537	541	were
O	542	550	assigned
O	551	553	to
O	554	557	TCC
O	558	560	or
O	561	564	CBT
O	564	565	-
O	565	566	I
O	567	570	for
O	571	572	2
O	572	573	-
O	573	577	hour
O	578	586	sessions
O	587	593	weekly
O	594	597	for
O	598	599	3
O	600	606	months
O	606	607	.

O	608	610	At
O	611	619	baseline
O	620	623	and
O	624	640	postintervention
O	640	641	,
O	642	647	blood
O	648	655	samples
O	656	660	were
O	661	669	obtained
O	670	673	for
O	674	685	measurement
O	686	688	of
O	689	690	C
O	690	691	-
O	691	699	reactive
O	700	707	protein
O	708	711	and
O	712	716	toll
O	716	717	-
O	717	721	like
O	722	730	receptor
O	730	731	-
O	731	732	4
O	732	733	-
O	733	742	activated
O	743	751	monocyte
O	752	762	production
O	763	765	of
O	766	777	interleukin
O	777	778	-
O	778	779	6
O	780	781	(
O	781	783	IL
O	783	784	-
O	784	785	6
O	785	786	)
O	787	790	and
O	791	796	tumor
O	797	805	necrosis
O	806	812	factor
O	812	813	-
O	813	814	α
O	815	816	(
O	816	819	TNF
O	819	820	)
O	820	821	,
O	822	826	with
O	827	828	a
O	829	835	random
O	836	845	subsample
O	846	847	(
O	847	848	n
O	849	850	=
B-total-participants	851	853	48
O	853	854	)
O	855	863	analyzed
O	864	866	by
O	867	873	genome
O	873	874	-
O	874	878	wide
O	879	894	transcriptional
O	895	904	profiling
O	904	905	.

B-outcome	906	912	Levels
I-outcome	913	915	of
I-outcome	916	917	C
I-outcome	917	918	-
I-outcome	918	926	reactive
I-outcome	927	934	protein
O	935	938	did
O	939	942	not
O	943	949	change
O	950	952	in
O	953	956	the
O	957	960	TCC
O	961	964	and
O	965	968	CBT
O	968	969	-
O	969	970	I
O	971	977	groups
O	977	978	.

O	979	985	Levels
O	986	988	of
O	989	993	toll
O	993	994	-
O	994	998	like
O	999	1007	receptor
O	1007	1008	-
O	1008	1009	4
O	1009	1010	-
O	1010	1019	activated
O	1020	1028	monocyte
O	1029	1039	production
O	1040	1042	of
O	1043	1045	IL
O	1045	1046	-
O	1046	1047	6
O	1048	1051	and
O	1052	1055	TNF
O	1056	1064	combined
O	1065	1071	showed
O	1072	1074	an
O	1075	1082	overall
B-outcome	1083	1092	reduction
I-outcome	1093	1095	in
I-outcome	1096	1099	TCC
I-outcome	1100	1106	versus
I-outcome	1107	1110	CBT
I-outcome	1110	1111	-
I-outcome	1111	1112	I
O	1113	1114	(
O	1114	1115	P
O	1116	1117	<
O	1118	1119	.
O	1119	1121	02
O	1121	1122	)
O	1122	1123	,
O	1124	1128	with
O	1129	1136	similar
O	1137	1144	effects
O	1145	1148	for
O	1149	1151	IL
O	1151	1152	-
O	1152	1153	6
O	1154	1155	(
O	1155	1156	P
O	1157	1158	=
O	1159	1160	.
O	1160	1162	07
O	1162	1163	)
O	1164	1167	and
O	1168	1171	TNF
O	1172	1173	(
O	1173	1174	P
O	1175	1176	<
O	1177	1178	.
O	1178	1180	05
O	1180	1181	)
O	1182	1187	alone
O	1187	1188	.

O	1189	1192	For
O	1193	1199	genome
O	1199	1200	-
O	1200	1204	wide
O	1205	1220	transcriptional
O	1221	1230	profiling
O	1231	1233	of
O	1234	1245	circulating
O	1246	1256	peripheral
O	1257	1262	blood
O	1263	1274	mononuclear
O	1275	1280	cells
O	1280	1281	,
O	1282	1292	expression
O	1293	1295	of
O	1296	1301	genes
O	1302	1310	encoding
O	1311	1326	proinflammatory
O	1327	1336	mediators
O	1337	1343	showed
O	1344	1346	an
O	1347	1354	overall
O	1355	1364	reduction
O	1365	1367	in
O	1368	1371	TCC
O	1372	1378	versus
O	1379	1382	CBT
O	1382	1383	-
O	1383	1384	I
O	1385	1386	(
O	1386	1387	P
O	1388	1389	=
O	1390	1391	.
O	1391	1394	001
O	1394	1395	)
O	1395	1396	.

O	1397	1402	TELiS
O	1403	1411	promoter
O	1411	1412	-
O	1412	1417	based
O	1418	1432	bioinformatics
O	1433	1441	analyses
O	1442	1452	implicated
O	1453	1454	a
B-outcome	1455	1464	reduction
I-outcome	1465	1467	of
I-outcome	1468	1476	activity
I-outcome	1477	1479	of
I-outcome	1480	1483	the
I-outcome	1484	1499	proinflammatory
I-outcome	1500	1513	transcription
I-outcome	1514	1520	factor
I-outcome	1520	1521	,
I-outcome	1522	1529	nuclear
I-outcome	1530	1536	factor
I-outcome	1536	1537	-
I-outcome	1537	1538	κ
I-outcome	1538	1539	B
O	1539	1540	,
O	1541	1543	in
O	1544	1555	structuring
O	1556	1561	these
O	1562	1573	differences
O	1573	1574	.

O	1575	1580	Among
O	1581	1587	breast
O	1588	1594	cancer
O	1595	1604	survivors
O	1605	1609	with
O	1610	1618	insomnia
O	1618	1619	,
O	1620	1621	3
O	1622	1628	months
O	1629	1631	of
O	1632	1635	TCC
O	1636	1643	reduced
B-outcome	1644	1652	cellular
I-outcome	1653	1665	inflammatory
I-outcome	1666	1675	responses
O	1675	1676	,
O	1677	1680	and
O	1681	1688	reduced
B-outcome	1689	1699	expression
I-outcome	1700	1702	of
I-outcome	1703	1708	genes
I-outcome	1709	1717	encoding
I-outcome	1718	1733	proinflammatory
I-outcome	1734	1743	mediators
O	1743	1744	.

O	1745	1750	Given
O	1751	1754	the
O	1755	1759	link
O	1760	1767	between
O	1768	1780	inflammation
O	1781	1784	and
O	1785	1791	cancer
O	1791	1792	,
O	1793	1798	these
O	1799	1807	findings
O	1808	1815	provide
O	1816	1818	an
O	1819	1827	evidence
O	1827	1828	-
O	1828	1833	based
O	1834	1843	molecular
O	1844	1853	framework
O	1854	1856	to
O	1857	1867	understand
O	1868	1871	the
O	1872	1881	potential
O	1882	1890	salutary
O	1891	1898	effects
O	1899	1901	of
O	1902	1905	TCC
O	1906	1908	on
O	1909	1915	cancer
O	1916	1928	survivorship
O	1928	1929	.
